ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 200

Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10

Vineesh Raveendran1, Jason Springer2, Donald Smith3, Mehrdad Maz4 and Kottarappat Dileepan1, 1Department of Medicine, University of Kansas Medical Center, Kansas City, KS, 2Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, 3University of Kansas Medical Center, Kansas City, KS, 4Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: giant cell arteritis, IL-6, interleukins (IL), mast cells and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Innate Immunity and Rheumatic Disease Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: IL-6 plays an important role in the pathogenesis of large vessel vasculitis.  Lipopolysaccharide (LPS), acting through toll-like receptor 4, enhances both the aortic expression as well as serum levels of IL-6.  Previous work by our group has demonstrated that systemic mast cell degranulation will inhibit both the serum and aortic expression of IL-6 in LPS injected mice.  Mast cells release many vasoactive substances including histamine, proteases, and IL-10 .  Our hypothesis is that the inhibitory effect of mast cells on aortic IL-6 production is mediated through histamine and/or IL-10.

Methods: Two month-old male C57BI6 (WT) and Histamine 1 Receptor (H1R) -/- mice were randomized into four groups, and given intraperitoneal injections with normal saline (control),  compound 48/80 (mast cell degranulation agent, 1mg/kg), LPS (1mg/kg) or C48/80+LPS.  Mice were sacrificed 24-h later, and levels of the stable metabolites of prostaglandin I2 (PGI2) and thromboxane A2 (TXA2) in the urine, and IL-6 and IL-10 in sera were quantified.

Results: MC degranulation did not increase PGI2 in control or in LPS-treated mice of either genotype. LPS injection increased PGI2 in both genotypes, but the increase was higher in H1R-/- mice. Both C48/80 and LPS increased TXA2 in WT mice, but only LPS treatment enhanced TXA2 in H1R-/-mice indicating importance H1R in this pathway.  Treatment with C48/80 did not further enhance prostanoid production over LPS.  LPS treatment increased serum IL-6 in both genotypes, but the changes were significant only in WT mice.  Interestingly, LPS-induced IL-6 production was significantly reduced by MC degranulation in WT mice, but not in H1R-/- mice.  In WT mice the inhibition of IL-6 was associated with enhanced aortic expression of SOCS1.  In comparison to WT, the basal and induced levels of IL-10 were markedly higher in H1R-/- mice. 

Conclusion: Mast cells differentially regulate LPS-induced inflammatory response in WT and H1R -/- mice.  These results suggest that MCs regulate LPS-induced systemic and aortic inflammatory response involving H1R, SOCS-1 and IL-10.

Acknowledgements: Supported by NIH grants R01-HL070101 & 3R01-HL070101-04S1, the Joseph & Elizabeth Carey Arthritis Fund and Audrey Smith Fund from KU Endowment Association, Lied Grant from KUMC Research Institute, and by the Department of Internal Medicine Research Office. H1R-null breeding pairs were graciously provided by Dr. Cory Teuscher, University of Vermont, Burlington, VT.


Disclosure: V. Raveendran, None; J. Springer, None; D. Smith, None; M. Maz, None; K. Dileepan, None.

To cite this abstract in AMA style:

Raveendran V, Springer J, Smith D, Maz M, Dileepan K. Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10 [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/mast-cell-regulation-of-aortic-il-6-expression-involves-histamine-1-receptor-suppressor-of-cyotkine-signaling-1-and-il-10/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mast-cell-regulation-of-aortic-il-6-expression-involves-histamine-1-receptor-suppressor-of-cyotkine-signaling-1-and-il-10/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology